Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 6:52 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1345–1368 of 6,233 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 1 Clear all

Conditions: Urothelial Carcinoma
Interventions: Livmoniplimab, Budigalimab, Docetaxel, Paclitaxel, Gemcitabine; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 11
States / cities: Springdale, Arkansas • San Francisco, California • New Haven, Connecticut + 8 more

Conditions: High Grade Glioma
Interventions: Magnetic Resonance (MR)-guided Laser Interstitial Thermal Therapy (LITT), Abacavir, Lamivudine, Ritonavir, Temozolomide, Focal Radiotherapy; Procedure · Drug · Radiation
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Miami, Florida

Conditions: HIV Infections
Interventions: GSK3640254, Placebo, Moxifloxacin; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Austin, Texas

Conditions: COVID-19, Coronavirus, Coronavirus Infections, SARS-CoV 2
Interventions: Hydroxychloroquine - Daily Dosing, Hydroxychloroquine - Weekly Dosing, Placebo oral tablet, Monitoring Visit - Baseline, Monitoring Visit - Week 4, Monitoring Visit - Week 8, Weekly Assessment; Drug · Other · Diagnostic Test
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years to 75 Years
Enrollment: 624 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Healthy
Interventions: LISTERINE COOL MINT Antiseptic Mouthwash, LISTERINE COOL MINT ZERO Alcohol Mouthwash, Reach Unflavored Waxed Dental Floss, Colgate Cavity Protection Toothpaste; Other
Lead sponsor: Johnson & Johnson Consumer Inc. (J&JCI); Industry
Eligibility: 18 Years and older
Enrollment: 284 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Fort Wayne, Indiana

Conditions: Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma
Interventions: MTD of Velcade, Nipent and Rituxan established in Part 1; Drug
Lead sponsor: Louisiana State University Health Sciences Center Shreveport; Other
Eligibility: 18 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Shreveport, Louisiana

Conditions: Aneurysm, Dissection, Aortic Root Aneurysm, Aortic Root Dissection, Carotid Artery Injuries, Aortic Arch, Bypass Extremity Graft, Occlusive Vascular Disease, Aortic Diseases
Interventions: Gelsoft Plus Vascular Graft, Vascular Bypass Graft, Cardiovascular Patch, Gelweave Vascular Graft, Gelweave Valsalva Vascular Graft; Device
Lead sponsor: Vascutek Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2037
U.S. locations: 10
States / cities: Aurora, Colorado • Tampa, Florida • Indianapolis, Indiana + 7 more

Conditions: COVID-19, Burnout, Burnout, Professional, Work-related Illness, Work-Related Stress, SARS-CoV-2 Infection
Interventions: Positive Affect Regulation sKills (PARK); Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 555 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Acute-graft-versus-host Disease, Chronic Graft-versus-host-disease, Solid Organ Transplant
Interventions: Ruxolitinib; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Up to 18 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Healthy
Interventions: PF-07258669, Itraconazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Hollywood, Florida

Conditions: Heart Failure
Interventions: Provider Focus, Patient Interview, PROs/Clinical Data Integration; Other
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 1,033 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Murray, Utah

Conditions: X-linked Retinoschisis, XLRS
Interventions: Dorzolamide 2% TID or brinzolamide 1% TID; Drug
Lead sponsor: Beacon Therapeutics; Industry
Eligibility: 7 Years and older · Male only
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 3
States / cities: Ann Arbor, Michigan • Portland, Oregon • Dallas, Texas

Conditions: Epilepsy, Seizures
Interventions: Perampanel; Drug
Lead sponsor: Carilion Clinic; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Roanoke, Virginia

Conditions: Wounds and Injuries, Mental Health
Interventions: Not listed
Lead sponsor: The Alternative Sexualities Health Research Alliance; Other
Eligibility: 18 Years and older
Enrollment: 917 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Rio Vista, California

Conditions: Solid Tumor, Adult
Interventions: SM08502; Drug
Lead sponsor: Biosplice Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 19
States / cities: Scottsdale, Arizona • Tucson, Arizona • Duarte, California + 14 more

Conditions: Muscular Atrophy, Spinal
Interventions: Nusinersen; Drug
Lead sponsor: Biogen; Industry
Eligibility: 7 Days and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 7
States / cities: Palo Alto, California • Aurora, Colorado • Chicago, Illinois + 4 more

Conditions: Relapse Multiple Myeloma, Refractory Multiple Myeloma
Interventions: Carfilzomib; Drug
Lead sponsor: Ajai Chari; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Phenylketonuria
Interventions: SYNB1934v1, Placebo; Drug
Lead sponsor: Synlogic; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 14
States / cities: Culver City, California • Orange, California • Palo Alto, California + 11 more

Conditions: Hypertension, Acute Severe Hypertension, Hypertensive Emergency, Hypertensive Urgency
Interventions: Tonlamarsen, Placebo; Drug
Lead sponsor: Kardigan, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 13
States / cities: Arvada, Colorado • Homestead, Florida • Port Orange, Florida + 10 more

Conditions: Classical Hodgkin Lymphoma
Interventions: CD30 CAR T-cell; Biological
Lead sponsor: New York Medical College; Other
Eligibility: 6 Years to 29 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2040
U.S. locations: 1
States / cities: Valhalla, New York

Conditions: Type 2 Diabetes Mellitus
Interventions: TAK-648, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 2
States / cities: Anaheim, California • Chula Vista, California

Conditions: Solid Tumor, Advanced Solid Tumor
Interventions: NL-201, Pembrolizumab Injection [Keytruda]; Drug
Lead sponsor: Neurogene Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 4
States / cities: New York, New York • Portland, Oregon • Houston, Texas + 1 more

Conditions: HepatoCellular Carcinoma, Unresectable HepatoCellular Carcinoma, Liver Cancer
Interventions: Stereotactic Body Radiation Therapy (SBRT), Sorafenib, Bavituximab; Radiation · Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Tourette Syndrome
Interventions: Continuous DBS, Responsive Brain Stimulation (RBS Setting); Device
Lead sponsor: University of Florida; Other
Eligibility: 21 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 1
States / cities: Gainesville, Florida

Search by objective public record fields.

Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)

STARLITE for Unresectable High-Grade Gliomas

Effect of Therapeutic and Supratherapeutic Oral Doses of GSK3640254 on Cardiac Conduction Compared to Placebo and a Single Oral Dose of Moxifloxacin

Will Hydroxychloroquine Impede or Prevent COVID-19

A Study of Virtually Supervised Mouth Rinses and Flossing

Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma

PANTHER Study of Terumo Aortic Knitted and Woven Grafts, and Cardiovascular Patches

Psychological Well-being and Burnout in Healthcare Workers During the COVID-19 (Coronavirus Disease 2019) Pandemic

Study of Ruxolitinib for Acute and Chronic Graft Versus Host Disease

A Study to Learn if the Study Medicine Called Itraconazole and if Food Changes How the Body Processes the Other Study Medicine Called PF 07258669 in Older Adults or Healthy Adults

Patient-Reported Outcomes as an Indicator of Disease Transitions in Heart Failure

Clinical Evaluation of Patients With X-linked Retinoschisis

Correlation of Serum Level of Perampanel (PER) Level to Cerebrospinal Fluid (CSF) Levels of PER

International Kink Health Study

A Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors

Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy

Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib

Efficacy and Safety of SYNB1934 in Patients With PKU (SYNPHENY-3)

Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension

CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma

TAK-648 Multiple-Rising Dose Study in Healthy Japanese Participants and Non-Japanese Participants With Type 2 Diabetes Mellitus

NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer

Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma

Tourette Syndrome Deep Brain Stimulation